Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Liabilities and Shareholders Equity (2019 - 2025)

Historic Liabilities and Shareholders Equity for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to $88.7 million.

  • Biodesix's Liabilities and Shareholders Equity fell 1364.67% to $88.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $359.9 million, marking a year-over-year decrease of 1109.81%. This contributed to the annual value of $97.2 million for FY2024, which is 186.89% down from last year.
  • As of Q3 2025, Biodesix's Liabilities and Shareholders Equity stood at $88.7 million, which was down 1364.67% from $87.7 million recorded in Q2 2025.
  • Over the past 5 years, Biodesix's Liabilities and Shareholders Equity peaked at $115.8 million during Q2 2024, and registered a low of $61.7 million during Q1 2022.
  • Over the past 5 years, Biodesix's median Liabilities and Shareholders Equity value was $87.7 million (recorded in 2025), while the average stood at $88.8 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first skyrocketed by 9334.65% in 2021, then crashed by 4661.6% in 2022.
  • Quarter analysis of 5 years shows Biodesix's Liabilities and Shareholders Equity stood at $76.1 million in 2021, then grew by 22.09% to $92.9 million in 2022, then rose by 6.66% to $99.1 million in 2023, then decreased by 1.87% to $97.2 million in 2024, then fell by 8.76% to $88.7 million in 2025.
  • Its last three reported values are $88.7 million in Q3 2025, $87.7 million for Q2 2025, and $86.2 million during Q1 2025.